IDEXX Laboratories, Inc. — Form 10-Q Summary
Business context and reporting period
Filed for the quarter ended March 31, 2014. IDEXX operates primarily through the Companion Animal Group (CAG), Water, and Livestock, Poultry and Dairy (LPD) segments, with other operations including OPTI Medical, pharmaceuticals, and out-licensing arrangements. The financial statements are unaudited and presented under U.S. GAAP.
Key financial metrics
| Metric | Q1 2014 | Q1 2013 | Change |
|---|---|---|---|
| Total revenue | $360.2 million | $332.1 million | 8.5% |
| Gross profit | $202.1 million | $184.0 million | 9.9% |
| Gross margin | 56.1% | 55.4% | +70 bps |
| Income from operations | $70.0 million | $61.2 million | 14.5% |
| Operating margin | 19.4% | 18.4% | +100 bps |
| Net income attributable to IDEXX | $46.6 million | $44.9 million | 3.8% |
| Diluted EPS | $0.89 | $0.81 | 9.9% |
| Net cash from operating activities | $33.5 million | $21.1 million | +$12.5 million |
Revenue growth was led by CAG, which increased 8.9% to $301.6 million, including 9.2% organic growth. Water revenue increased 3.7% to $21.4 million, LPD increased 11.8% to $31.4 million, and Other revenue declined 9.6% to $5.8 million.
CAG recurring diagnostics revenue increased 8.0%, supported by higher reference laboratory volumes, VetLab consumables, pricing, and customer retention. Rapid assay revenue declined 2.3%, partly because distributor inventory changes reduced growth. Reference laboratory revenue rose 9.9%, while capital instrument revenue increased 17.2%.
At March 31, 2014, cash and cash equivalents were $286.2 million, working capital was $166.0 million, and total debt was approximately $466.1 million, consisting primarily of $315.0 million drawn on the revolving credit facility and $150.1 million of long-term debt. Remaining borrowing availability under the credit facility was $134.0 million. The company reported compliance with its debt covenants.
Investing cash outflows were $12.6 million, including $11.3 million of capital expenditures and $1.2 million for an acquisition. Management estimated approximately $80 million of capital expenditures for full-year 2014. Financing cash outflows were $15.0 million, including $70.3 million of share repurchases, partly offset by $38.0 million of net revolving-facility borrowings and $11.0 million of proceeds from equity exercises and employee plans.
Material changes versus the prior comparable period
- Operating income increased faster than revenue, reflecting gross-margin expansion and lower unallocated operating costs.
- Interest expense increased to $2.8 million from $0.8 million, primarily because of the $150 million of senior notes issued in December 2013.
- The effective tax rate rose to 31.2% from 26.2% because the U.S. research and development tax credit benefited the prior-year quarter and had expired as of January 1, 2014.
- Net income growth was limited by higher interest expense and the higher tax rate, although diluted EPS benefited from a lower share count following repurchases.
- Operating cash flow improved primarily because working-capital changes were less unfavorable than in the prior year, particularly inventory and accrued liabilities.
- Q1 2014 included a $4.1 million improvement in unallocated operating expenses because Q1 2013 included a loss related to the bankruptcy of a freight payment and audit service provider.
- The company repurchased 575,859 shares under its repurchase program for $70.3 million; 2.4 million shares remained authorized for repurchase at March 31, 2014.
Guidance, outlook, risks, contingencies, and unusual items
The filing does not provide specific full-year revenue or earnings guidance. Management stated that cash on hand, operating cash flow, and available borrowings are expected to fund operations, capital requirements, and strategic growth needs for at least the next twelve months.
- Reported revenue was reduced by approximately $0.7 million by currency movements. Approximately 27% of consolidated revenue was derived from products manufactured in the United States and sold internationally in local currencies.
- Distributor inventory levels can materially affect reported CAG consumables and rapid assay revenue and may not reflect underlying end-user demand.
- Economic conditions may affect veterinary visits, clinic capital purchases, water testing, livestock testing, and customer pricing sensitivity.
- Foreign currency, interest-rate, and debt risks are managed in part through derivatives. The notional amount of foreign-currency contracts was $179.0 million at March 31, 2014.
- Approximately $284.5 million of cash was held by foreign subsidiaries and was subject to material potential repatriation tax effects. The company has not provided for taxes on earnings considered indefinitely reinvested outside the United States.
- Pending and threatened legal matters arise in the ordinary course of business. Management does not expect currently pending matters to have a material effect, but unfavorable resolutions could affect a particular period.
- Patents and third-party licenses expected to expire in 2014 and 2015 are not expected by management to have a material effect, although this remains subject to market and regulatory conditions.
- The filing includes a nonmaterial revision to Q1 2013 cash-flow classifications that increased operating cash flow and decreased investing cash flow by $0.4 million.
Important facts for investors to verify
- Whether CAG recurring revenue growth and reference laboratory testing volumes remain durable after adjusting for pricing, distributor inventories, acquisitions, and currency.
- The effect of the expired U.S. R&D tax credit and the resulting effective tax rate on subsequent quarters.
- Debt reduction, interest expense, and compliance with the 3.0-to-1 credit-facility leverage covenant and 3.5-to-1 senior-note covenant.
- Execution of the approximately $80 million 2014 capital expenditure plan and its impact on free cash flow.
- The sustainability of large share repurchases relative to operating cash generation and borrowing levels.
- Potential tax costs associated with repatriating foreign cash and earnings.
- Exposure to foreign currency movements, distributor purchasing patterns, economic conditions, competition, patent expirations, and ordinary-course litigation.